What happened to Oncology?

Anonymous

Guest
Cephalon was never an Oncology Company. They recruited some decent Oncology reps but couldn't really attract the best ones from the better biotechs because they paid less salary and offered no stock options. Even those Oncology reps who just have big-pharma Oncology experience are leaving....
These CNS and pain reps view the Oncology positions as promotions. The company is doing a good thing by saving their jobs while at the same time allowing seasoned Oncology reps to leave. A lot of us have been in the Oncology business for many years and have never seen anything like this.. Close to 30 Oncology reps have left....amazing! There will be more over the next 16 months. A lot of existing reps find themselves in areas where ex-Genetech managers have new positions and are hiring their own. This will settle down eventually, there will be new opportunities and more will leave.
The new people coming in(CNS,Pain) will realize their salaries in Oncology will be the lowest in the industry. The ability to make excellent bonus is also severely impaired due to the MBO situation and in a couple of years they will be out on the market contributing to the expensive turn over situation at Cephalon/Teva. The market place will offer opportunity in the next couple of years - even the big pharma Oncology opportunities will offer better money than Cephalon because the newbies will be so far behind the eight ball with those CNS/Pain salaries. Cephalon won't be able to make up the difference fast enough. Incyte is paying experienced reps bases in the $130-$145 range this does not include bonus and options.
Employees should have been offered retention bonuses to stay and compliance should have been directed where the real problem started which was in the other divisions. You can't control Oncologists and their prescribing habits, they are trying to extend and save lives and will combine, subtract etc... in order to find the best result. This sales force has not been selling "off label"......These surveys are flawed and are just a mechanism by which to show the government Cephalon is playing ball and upper management's stock option payouts are protected. Good luck to you and your families.....you are just disposable pawns in this game....
 












Cephalon was never an Oncology Company. They recruited some decent Oncology reps but couldn't really attract the best ones from the better biotechs because they paid less salary and offered no stock options. Even those Oncology reps who just have big-pharma Oncology experience are leaving....
These CNS and pain reps view the Oncology positions as promotions. The company is doing a good thing by saving their jobs while at the same time allowing seasoned Oncology reps to leave. A lot of us have been in the Oncology business for many years and have never seen anything like this.. Close to 30 Oncology reps have left....amazing! There will be more over the next 16 months. A lot of existing reps find themselves in areas where ex-Genetech managers have new positions and are hiring their own. This will settle down eventually, there will be new opportunities and more will leave.
The new people coming in(CNS,Pain) will realize their salaries in Oncology will be the lowest in the industry. The ability to make excellent bonus is also severely impaired due to the MBO situation and in a couple of years they will be out on the market contributing to the expensive turn over situation at Cephalon/Teva. The market place will offer opportunity in the
next couple of years - even the big pharma Oncology opportunities will offer better money
than Cephalon because the newbies will be so far behind the eight ball with those CNS/Pain
salaries. Cephalon won't be able to make up the difference fast enough. Incyte is paying
experienced reps bases in the $130-$145 range this does not include bonus and options.
Employees should have been offered retention bonuses to stay and compliance should havebeen directed where the real problem started which was in the other divisions. You can'tcontrol Oncologists and their prescribing habits, they are trying to extend and save lives and will combine, subtract etc... in order to find the best result. This sales force has not been
selling "off label"......These surveys are flawed and are just a mechanism by which to show
the government Cephalon is playing ball and upper management's stock option payouts are
protected. Good luck to you and your families.....you are just disposable pawns in this
game....

Absolutely wrong on salaries. Cephalon is not the highest in the oncology industry for salaries, but they were able to recruit 90 percent of the people they wanted from other oncology companies. Sanofi, Biogen, you name the company and we had no issue with salaries for the vast majority of people we wanted.
Unfortunately a minority companies grant stock options to the sales force at this time in the industry. With Incyte, those folks are taking a big risk. And is often the case with small start-ups they pay higher salaries / stock options to overcome the fear of an ODAC thumbs down.
Other than that I agree with everything else in that quote. Compliance and upper management could care less about a poorly designed survey or the inherent nature of off-label usage within oncology. Upper management needs scapegoats and they will find them.
Spineless leaders like MS want upward mobility, so he will take care of BC at all costs. Too bad, MS is a personable guy, but totally lacks the respect of the people he leads.
 












Well said! Cephalon has forgotten one thing, those of us whom have left have the relationships with the offices and could cause a ripple effect of retaliation against Cephalon i.e., cause the offices to refuse access to new reps! Never underestimate the power of relationships!

Teva should judge upper management by attrition rates! All of their asses would be out of a job!!!! 30 people and counting is pathetic!!!
 




































BC MS BB CT are getting exactly what they want: reduced salaries, reduced bonus, elimination of the negative reps, saving mgt jobs by keeping oncology territories filled. teva will not eliminate mgt that has reached $1b in sales of a drug that was forecast at half that number.

looks like SUCCESS from the outside!
 






BC MS BB CT are getting exactly what they want: reduced salaries, reduced bonus, elimination of the negative reps, saving mgt jobs by keeping oncology territories filled. teva will not eliminate mgt that has reached $1b in sales of a drug that was forecast at half that number.

looks like SUCCESS from the outside!

CT is lost in Oncology.
 






Absolutely wrong on salaries. Cephalon is not the highest in the oncology industry for salaries, but they were able to recruit 90 percent of the people they wanted from other oncology companies. Sanofi, Biogen, you name the company and we had no issue with salaries for the vast majority of people we wanted.
Unfortunately a minority companies grant stock options to the sales force at this time in the industry. With Incyte, those folks are taking a big risk. And is often the case with small start-ups they pay higher salaries / stock options to overcome the fear of an ODAC thumbs down.
Other than that I agree with everything else in that quote. Compliance and upper management could care less about a poorly designed survey or the inherent nature of off-label usage within oncology. Upper management needs scapegoats and they will find them.
Spineless leaders like MS want upward mobility, so he will take care of BC at all costs. Too bad, MS is a personable guy, but totally lacks the respect of the people he leads.


The situation was a promotion from those coming from the Sanofi's of the world but not other companies. Some took pay cuts in order to be employed due to downsizing etc.. The job market wasn't the best.
So lets look at the option/Grant scenario......

Seattle Genetics Options
Dendreon Options
Incyte Options
Celgene Options(Quarterly)

Onyx Options
Alexion Options
Allos Options
AMAG Options
Gilead Options(will be an Oncology player in the near future)
Milleneum Options until recent buy out
OSI Options until recent buy out
Genzyme Options until recent buy out
Amgen Options
Cephalon-------never to reps

Big pharma is left out..not a lot of desire to work there from the above companies. Options are pretty much the norm for this class of company and will be in the future. Dendreon, Allos,Amag....hold a lot of risk. Fair to project reps have either made money with their options or will from the other companies.
 






BC MS BB CT are getting exactly what they want: reduced salaries, reduced bonus, elimination of the negative reps, saving mgt jobs by keeping oncology territories filled. teva will not eliminate mgt that has reached $1b in sales of a drug that was forecast at half that number.

looks like SUCCESS from the outside!


They will be behind the eight ball on salaries from CNS and Pain.......There is a 40 grand difference in a lot of cases.... Do you really think Teva will give them raises to bring them up to Oncology averages in 2 years? I don't think so....these people will go elsewhere along with more seasoned vets down the road as the opportunities materialize.